Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Osteoarthritis of the Knee
Sponsor: UCB Pharma
Terminated
Based on the outcome of the planned first interim analysis, it was decided not to continue the trial. No safety concerns were identified.
Other terminated trials from UCB Pharma
Other Osteoarthritis trials with similar outcome
This PHASE2 trial investigates Osteoarthritis and is currently terminated or withdrawn. UCB Pharma leads this study, which shows 12 recorded versions since 2007 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Sep 2017 — May 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — Sep 2017 [monthly]
Terminated PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UCB Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Hersfeld, Germany , Berlin, Germany , Bialystok, Poland , Brăila, Romania , Debrecen, Hungary , Esztegom, Hungary , Gyula, Hungary , Győr, Hungary , Hamburg, Germany , Kladno, Czechia and 16 more locations